SCHEMBL5009753

SCHEMBL5009753

COC(C(N)=O)c1ccc(C(=O)O)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
CA1 P00915 4/20 0.47
CA2 P00918 4/20 0.47
ANPEP P15144 1/20 0.44
TP53 P04637 1/20 0.44
TSHR P16473 1/20 0.44
CA12 O43570 3/20 0.43
CA9 Q16790 3/20 0.43
ALDH1A1 P00352 2/20 0.43
CA4 P22748 2/20 0.43
CA6 P23280 2/20 0.43
CA7 P43166 2/20 0.43
CA14 Q9ULX7 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
GAA P10253 1/20 0.43
PARP15 Q460N3 1/20 0.43
PARP10 Q53GL7 1/20 0.43
TPMT P51580 1/20 0.43
F2 P00734 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5008293 0.84 GAA (0.56) KMT2ASMN1; SMN2CA1CA2TSHR
SCHEMBL8476179 0.82 KMT2A (0.57) KMT2ASMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL1068632 0.82 KMT2A (0.57) KMT2ASMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL11903287 0.82 KMT2A (0.57) KMT2ASMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL4516249 0.81 CA1 (0.47) KMT2ASMN1; SMN2CA1CA2ANPEP
SCHEMBL4280687 0.81 ESR1 (0.42) KMT2ASMN1; SMN2CA1CA2TSHR
SCHEMBL1815681 0.80 PTGS2 (0.50) KMT2ASMN1; SMN2ALDH1A1L3MBTL1GAA
SCHEMBL27485681 0.80 ANPEP (0.51) KMT2ASMN1; SMN2CA1CA2ANPEP
SCHEMBL29921041 0.79 KMT2A (0.45) KMT2ASMN1; SMN2TSHRALDH1A1L3MBTL1
SCHEMBL18920888 0.79 CA1 (0.52) KMT2ACA1CA2TSHRALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP claimed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US claimed
EP-1884513-A1 PYRAZOLE COMPOUND AND THERAPEUTIC AGENT FOR DIABETES COMPRISING THE SAME Japan Tobacco, Inc. (JP) 2008-02-06 EP disclosed
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents JAPAN TOBACCO INC. (JP) 2007-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032529-A1 Pyrazole compounds and their use as antidiabetes agents PYGL, GYS2, AGL KMT2A 4487/4885SMN1; SMN2 4705/4885CA1 1635/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.